European shares were at a record high on Friday, led by technology and healthcare stocks, even as caution prevailed ahead of ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Crypto is in a cooling period after running to a new record last week and was pulled lower by the DeepSeek-driven sell-off in tech stocks.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

S&P 500 futures steady after record highs. Novo Nordisk and Twilio surge, while Boeing posts $4B loss. Traders eye Fed policy ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

Despite these results, Novo Nordisk's stock experienced a downturn, which may reflect investor concerns over the commercial implications or regulatory prospects of the new dosage. The trial outcomes ...